The FDA approved adalimumab-atto (Amjevita, Amgen) as a biosimilar to adalimumab (Humira, AbbVie) for multiple inflammatory diseases—the fourth biosimilar to be approved in the United States.
Adalimumab-atto is approved for the following indications in adult patients:
• moderately to severely active rheumatoid arthritis;
• active psoriatic arthritis;
• active ankylosing spondylitis;
• moderately to severely active Crohn’s disease;
• moderately to severely active